title: A New Level A Type IVIVC for the Rational Design of Clinical Trials Toward Regulatory Approval of Generic Polymeric Long-Acting Injectables.
abstract: Chronic neuropsychiatric disorders and diabetes mellitus affect millions of patients and require long-term supervision and expensive medical care. Although repeated drug administration can help manage these diseases, relapses and re-hospitalization owing to patient non-adherence and reduced therapeutic efficacy remain challenging. In response, long-acting injectables, which provide sustained drug release over longer periods at concentrations close to therapeutic ranges, have been proposed. Recent advancements include polymeric long-acting injectables (pLAIs), in which the active pharmaceutical ingredient (API) is encapsulated within U.S. Food and Drug Administration (FDA)-approved biocompatible polymers, such as poly(lactic-co-glycolic acid), or PLGA. Despite significant progress and development in the global pLAI market, FDA guidance for the approval of complex drug products, such as generic pLAIs, is not clearly defined. Although in vitro to in vivo correlation (IVIVC) can facilitate the identification of critical quality attributes (CQAs), drug formulations, and in vitro test platforms for evaluating drug performance in vivo, the application of IVIVC in order to shortlist time- and resource-intensive clinical trials for generic pLAIs has not been reported. Here, we propose a new Level A Type IVIVC that directly correlates the in vitro outcomes, such as drug dissolution, of candidate generic formulations with the clinical characteristics, such as drug absorption, of a reference listed drug (RLD), to help identify the specific generic pLAI formulations with clinical absorptions that are likely to be similar to that of the RLD, thereby reducing the number of clinical trials required for evaluation of clinical bioequivalence (BE). Therefore, the scope of the proposed method is intended only for the rational design of clinical trials, i.e., to shortlist the specific pLAI generic formulations for clinical BE evaluation, and not necessarily to analyze drug performances (i.e., drug safety and effectiveness) in the shortlisted clinical trials or post-approval. Once validated, this method will be of great value to developers of generic pLAIs and regulatory bodies to accelerate their approval of these generic pLAIs.
authors.affiliation: Computational Medicine and Biology Division, CFD Research Corporation, 701 McMillian Way NW, Suite D, Huntsville, AL, 35806, USA. mrsomayaji@gmail.com.
authors.forename: Mahadevabharath R
authors.identifier: 0000-0002-2317-3305
authors.initials: MR
authors.lastname: Somayaji
authors.affiliation: Computational Medicine and Biology Division, CFD Research Corporation, 701 McMillian Way NW, Suite D, Huntsville, AL, 35806, USA.
authors.forename: Debarun
authors.initials: D
authors.lastname: Das
authors.affiliation: Computational Medicine and Biology Division, CFD Research Corporation, 701 McMillian Way NW, Suite D, Huntsville, AL, 35806, USA.
authors.forename: Andrzej
authors.initials: A
authors.lastname: Przekwas
mesh_terms: D002626:Chemistry, Pharmaceutical / Q000379:methods*; D003692:Delayed-Action Preparations; D017277:Drug Approval / Q000379:methods*; D065546:Drug Liberation; D016568:Drugs, Generic / Q000493:pharmacokinetics*; D006801:Humans; D066298:In Vitro Techniques / Q000379:methods*; D007267:Injections / Q000379:methods*; D011108:Polymers / Q000493:pharmacokinetics*; D013810:Therapeutic Equivalency; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D003692:Delayed-Action Preparations; D016568:Drugs, Generic; D011108:Polymers